Share
News
-
20 October 2010 /Prices and reimbursement
General reimbursement for medicines containing losartan in combination with hydrochlorothiazide
Patients can now receive general reimbursement for all medicines containing losartan in combination with hydrochlorothiazide. This also includes medicines containing a combination of losartan 100 mg and hydrochlorothiazide 12.5 mg
-
14 June 2010 /Prices and reimbursement
Change of the reimbursement for certain cardiovascular products as of 15 November 2010
The Reimbursement Committee and the Danish Medicines Agency have reviewed some of the medicinal products used for the treatment of cardiovascular disease (antihypertensives) in order to assess whether they meet the criteria for public reimbursement. The medicinal products concerned are the so-called angiotensin II antagonists and renin inhibitors.
-
14 June 2010 /Prices and reimbursement
Changes in reimbursements for anti-ulcer medicines
The Reimbursement Committee and the Danish Medicines Agency have reviewed medicinal products for the treatment of heartburns, sour eructations and ulcers ('acid-related disorders') in order to assess whether they meet the criteria for public reimbursement.
-
03 June 2010 /Prices and reimbursement
Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)
The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors) was open for consultation until 7 May 2010.
-
21 April 2010 /Prices and reimbursement
Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists
On 16 April 2010, the Danish Medicines Agency decided on the future reimbursement status of some of the losartan-containing medicines in ATC groups C09C and C09D, making these products eligible for general reimbursement as of 19 April 2010.
-
09 April 2010 /Prices and reimbursement
Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)
The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders) was open for consultation until 15 March 2010.
-
31 March 2010 /Prices and reimbursement
Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors).
-
24 March 2010 /Prices and reimbursement
The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of medicines in ATC groups C09C, C09D and C09X
On 8 March 2010, a number of pharmaceutical companies put generic copies of the angiotensin II antagonist losartan on the market at prices comparable to those of the cheapest ACE inhibitors.
-
19 February 2010 /Prices and reimbursement
Reassessment of the reimbursement status of ATC group A – alimentary tract and metabolism
The Danish Medicines Agency will begin its reassessment of ATC group A, alimentary tract and metabolism, which includes.
-
26 January 2010 /Prices and reimbursement
Change of the content of the fields ’Number of DDD per package’ and ’Price per DDD’
Users of ftp.dkma.dk, www.medicinpriser.dk and www.erhverv.medicinpriser.dk should note that the content of two fields in the LMS files at ftp.dkma.dk changed on 16 November 2009.
-
07 January 2010 /Prices and reimbursement
The Danish Medicines Agency initiates the reassessment of reimbursement status of medicines in ATC group N
The Danish Medicines Agency initiates its reassessment of the reimbursement status of medicines in ATC group N (Nervous system). It will take place concurrently with the reassessment process for the remaining subgroups in ATC groups A and J.
